Ovarian Cancer News and Research RSS Feed - Ovarian Cancer News and Research Twitter

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics, Inc. today announced that its Tumor BRACAnalysis CDx- companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain. [More]
FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. [More]
Lya Segall Ovarian Cancer Institute at Mercy opens in Maryland

Lya Segall Ovarian Cancer Institute at Mercy opens in Maryland

Mercy Medical Center has announced the opening of The Lya Segall Ovarian Cancer Institute at Mercy, the first center in Maryland specifically designed and dedicated solely for the diagnosis and treatment of ovarian cancer. [More]
Study identifies potential way to improve treatment for chemo-resistant ovarian cancer

Study identifies potential way to improve treatment for chemo-resistant ovarian cancer

Ovarian cancer is the most deadly gynecological cancer, claiming the lives of more than 50% of women who are diagnosed with the disease. [More]
ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ImmunoCellular Therapeutics, Ltd. announced today that it has established a licensing agreement with the California Institute of Technology for exclusive rights to novel technology for the development of certain antigen specific T-cell immunotherapies for the treatment of cancer. [More]
Researchers develop protein therapy that may stop cancer growth

Researchers develop protein therapy that may stop cancer growth

A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body. [More]
Genetic testing for breast cancer doubled due to 'Angelina Jolie effect'

Genetic testing for breast cancer doubled due to 'Angelina Jolie effect'

In May 2013 Angelina Jolie, who was then Hollywood's highest-paid actress, underwent a double mastectomy after testing positive for a BRCA1 gene mutation that significantly increases the risk of developing breast cancer. A recent study, published by Breast Cancer Research has found that, public knowledge of her decision doubled NHS referrals for genetic testing for breast cancer risk. [More]
Curie-Cancer, Inventiva launch Epicure project that aims to develop epigenetic targets for cancer

Curie-Cancer, Inventiva launch Epicure project that aims to develop epigenetic targets for cancer

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR [Agence Nationale pour la Recherche]. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

The ovarian cancer market is highly active with several promising candidates having reached the late stages of development. Three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in mutated [BRCA-deficient] cancer cells, have been identified by Datamonitor Healthcare as front runners. [More]
Researchers identify non-protein-coding RNA whose expression linked to ovarian cancer

Researchers identify non-protein-coding RNA whose expression linked to ovarian cancer

Over the years researchers have made tremendous strides in the understanding and treatment of cancer by searching genomes for links between genetic alterations and disease. [More]
Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Oncolytics Biotech Inc. today announced that patient enrollment has been completed in a randomized Phase 2 study of paclitaxel plus REOLYSIN® versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). [More]
VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy. [More]
UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern Medical Center faculty have received 19 grants totaling more than $26 million from the Cancer Prevention and Research Institute of Texas to expand cancer screenings, investigate the effectiveness and viability for cancer therapies and radiation treatments, conduct research into cancer biology, and recruitment. [More]
Physically active men are at lower risk of nocturia

Physically active men are at lower risk of nocturia

Men who are physically active are at lower risk of nocturia (waking up at night to urinate), according to a study led by a Loyola University Chicago Stritch School of Medicine researcher. [More]
Couples' health rights raised in gay marriage case

Couples' health rights raised in gay marriage case

As part of the court fight to overturn the ban on gay marriage in Wisconsin and Indiana, couples are pointing to problems they have in medical emergencies when their partners are not recognized. [More]
Experts available to share tips on prevention of ovarian cancer

Experts available to share tips on prevention of ovarian cancer

Ovarian cancer is the fourth leading cause of death in American women, with about 22,000 diagnosed and 14,000 dying from the disease each year. September is Ovarian Cancer Awareness month and Mount Sinai experts are sharing tips on prevention. [More]
CD157 important in malignant pleural mesothelioma

CD157 important in malignant pleural mesothelioma

CD157 plays a pivotal role in the progression of malignant pleural mesothelioma and may be useful in the stratification of patients into different prognostic groups, Italian research suggests. [More]
Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. [More]
Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

A leukemia drug called dasatinib shows promise for treating skin, breast and several other cancers, according to researchers at Loyola University Chicago Stritch School of Medicine. [More]